Product profile
CJC-1295 (with DAC)
Overview
A modified synthetic analog of growth hormone-releasing hormone (GHRH) with a drug affinity complex for extended half-life, studied for sustained pituitary GH release and endocrine signaling pathways.
- Concentration
- 5 mg
- Stock
- In stock
Product details
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH 1-29) engineered with a drug affinity complex (DAC) moiety that promotes reversible binding to serum albumin, significantly extending its plasma half-life and duration of action compared to unmodified GHRH fragments.
- Structure: Modified GHRH(1-29) with DAC extension for prolonged activity
- Key Modification: Albumin-binding domain for extended pharmacokinetics
- Research Applications: Pituitary somatotroph stimulation, pulsatile GH patterns, IGF-1 pathway exploration
- Common Models: Rodent and primate pituitary function studies, metabolic homeostasis experiments
- Mechanistic Interests: cAMP accumulation, GHRH receptor activation, long-term GH axis modulation
It is used in research to investigate sustained pituitary growth hormone release, cyclic AMP-mediated signaling cascades, somatotropic axis dynamics, and endocrine feedback regulation in preclinical endocrine and metabolic model systems.
All products currently listed on this site are for research purposes only.
